Loading…
Gene-editing biotech that co-developed Casgevy, the first approved CRISPR therapy, for sickle cell disease and beta-thalassemia.
Gene-editing biotech that co-developed Casgevy, the first approved CRISPR therapy, for sickle cell disease and beta-thalassemia.
Does not sell Casgevy itself: Vertex runs commercialisation and the two split costs and profits, so CRISPR's income depends on how many patients complete the lengthy treatment process at authorised centres. Beyond that it funds research from its cash reserves, with in-house gene-editing programmes for heart disease and diabetes.
Moat: narrow (IP / patents, process know-how). A foundational CRISPR/Cas9 patent estate and being first to market with an approved gene-editing cure.
Headquarters: Zug, Switzerland · Founded: 2013
Size CRISPR Therapeutics (CRSP) is a United States Health Care company (Biotechnology) with a market value of $4.86B, the 1203rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $50.07 on 6 Nov 2026.
Performance Over six months the shares fell 8.7%, against +2.4% for the median peer and -1.1% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue fell 34.3% over the last twelve months (peer median +9.9%); the operating margin is -2,058.6% (peer median -7.8%).
Valuation It trades at 133.6× enterprise value to sales against a peer median of 12.4× (3rd most expensive of 15).
Short interest Short interest is 17.0% of the free float (15 Oct 2026).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $25.2M | $3.51M | $37.3M | $371M | $1.20M |
| Revenue growth | — | -91% | -90% | +30,885% | — |
| Gross profit | -$174M | -$229M | -$92.2M | $221M | -$133M |
| EBITDA | -$500M | -$549M | -$447M | -$203M | -$649M |
| Net income | -$456M | -$582M | -$366M | -$154M | -$650M |
| Free cash flow | -$377M | -$346M | -$145M | -$270M | -$533M |
| Capital expenditure | $2.08M | $914,000 | $1.90M | $9.47M | $37.2M |
| Total debt | $780M | $207M | $224M | $239M | $244M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| CRISPR Therapeutics CRSP | $4.86B | -9% | -34% | -2,059% | 133.6× | n/a |
| Intellia Therapeutics NTLA | $1.59B | -19% | +13% | -712% | 20.6× | n/a |
| Editas Medicine EDIT | $395M | -17% | +21% | -178% | 5.4× | n/a |
| Vertex Pharmaceuticals VRTX | $139B | +27% | +11% | 35% | 10.7× | 6.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CRSP | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.7% | +3.8% | 7th lowest of 21 |
| 6-month return | -8.7% | +2.4% | 7th lowest of 21 |
| Distance from 52-week high | -21.1% | -24.0% | 9th highest of 21 |
| Revenue growth (TTM) | -34.3% | +9.9% | 2nd lowest of 15 |
| Operating margin | -2,058.6% | -7.8% | 3rd lowest of 15 |
| EV / Sales | 133.6× | 12.4× | 3rd most expensive of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | 133.6× | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.89B | -11% | -22% | 17% | 5.7× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.89B | +28% | n/a | n/a | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.81B | -1% | -61% | -11,441% | 2,087.9× | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.92B | -34% | +102% | 61% | 1.2× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.72B | -37% | +8% | -35% | 14.5× | n/a | n/a |
| Joinn Laboratories (China) 603127.SS | China | $4.58B | +15% | +12% | -4% | 15.1× | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.51B | -13% | -18% | -1% | 2.8× | 32.2% | +7.1% |
| Adaptive Biotechnologies ADPT | United States | $4.47B | +103% | +50% | -12% | 14.7× | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.35B | -2% | -28% | -210% | 5.4× | -6.4% | -10.0% |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 24.9× | 36.7% | +26.2% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $5.58B | -6% | +16% | 10% | 5.4× | 28.4% | +16.4% |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | 308.8× | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | 51.7× | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 4.8× | 3.2% | +12.5% |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | 10.4× | n/a | n/a |